Immunocore (NASDAQ:IMCR) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Immunocore (NASDAQ:IMCR) in a research report report published on Monday morning, Benzinga reports.

Other analysts have also recently issued reports about the company. Oppenheimer restated an outperform rating and set a $89.00 price target (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Barclays decreased their price target on shares of Immunocore from $92.00 to $66.00 and set an overweight rating for the company in a research report on Friday, August 9th. Needham & Company LLC reiterated a buy rating and set a $81.00 price target on shares of Immunocore in a report on Friday, August 9th. JPMorgan Chase & Co. decreased their price objective on Immunocore from $70.00 to $66.00 and set an overweight rating for the company in a report on Wednesday, July 10th. Finally, HC Wainwright reaffirmed a buy rating and set a $100.00 target price on shares of Immunocore in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $80.70.

Immunocore Trading Up 1.4 %

IMCR opened at $33.87 on Monday. The company has a market cap of $1.69 billion, a P/E ratio of -27.76 and a beta of 0.73. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The company’s 50 day moving average is $37.52 and its 200-day moving average is $48.41. Immunocore has a 1-year low of $33.04 and a 1-year high of $76.98.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The company had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. During the same period in the prior year, the business earned ($0.37) earnings per share. The company’s revenue for the quarter was up 26.2% compared to the same quarter last year. Equities research analysts predict that Immunocore will post -1.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. DNB Asset Management AS boosted its holdings in shares of Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after buying an additional 1,868 shares in the last quarter. NEOS Investment Management LLC bought a new position in Immunocore during the fourth quarter worth $262,000. XTX Topco Ltd acquired a new stake in Immunocore in the second quarter worth $303,000. Tidal Investments LLC acquired a new stake in Immunocore in the first quarter worth $423,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Immunocore by 69.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after purchasing an additional 2,721 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.